Publications by authors named "M Janning"
Navigating in diverse environments to find food, shelter, or mating partners is an important ability for nearly all animals. Insects have evolved diverse navigational strategies to survive in challenging and unknown environments. In the insect brain, the central complex (CX) plays an important role in spatial orientation and directed locomotion.
View Article and Find Full Text PDFArticle Synopsis
- Circulating tumor cells (CTCs) are critical for understanding tumor diversity and treatment resistance, but traditional methods often capture low numbers, especially in non-small cell lung cancer (NSCLC).
- This study utilized diagnostic leukapheresis (DLA) on six advanced NSCLC patients to access larger blood volumes and employed a new two-step method to enrich CTCs for analysis.
- The results unveiled 3,363 unique CTC transcriptomes, revealing significant heterogeneity and potential distinct phenotypes, which suggests CTCs can serve as valuable indicators for tumor monitoring and targeted therapies in the future.
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program.
View Article and Find Full Text PDFIntroduction: Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC in the clinical routine, but it has limited value in distinguishing responses. Assessment of KRAS and TP53 mutations (mut) as surrogate for an immunosupportive tumor microenvironment (TME) might help to close this gap.
Methods: A total of 696 consecutive patients with programmed death-ligand 1-high (≥50%), nonsquamous NSCLC, having received molecular testing within the German National Network Genomic Medicine Lung Cancer between 2017 and 2020, with Eastern Cooperative Oncology Group performance status less than or equal to 1 and pembrolizumab as first-line palliative treatment, were included into this retrospective cohort analysis.
Article Synopsis
- ctDNA analysis offers a minimally invasive method for treatment decision-making and monitoring cancer, particularly in patients with advanced-stage non-small cell lung cancer (NSCLC).
- In a study of 72 patients, the UltraSEEK Lung Panel demonstrated a high detection rate (over 90%) for tumor-specific mutations in circulating cell-free DNA (ccfDNA), showing good accuracy compared to droplet digital PCR and traditional tumor tissue testing.
- A significant decrease in ctDNA levels shortly after treatment initiation was linked to longer progression-free survival (PFS) and overall survival (OS), indicating that ccfDNA can effectively track treatment response in NSCLC patients.